For example, requesting a quantity of 30 for a 90-day supply for a once-daily medication is a common mistake that flags the request for review or causes rejection
The first GLP-1 drug to receive FDA approval in 2005 was Amylin/Lilly's Byetta, administered as a twice-daily injection for the treatment of type 2 diabetes
Momenta Weight Loss Program Losing weight is a challenge
Until then, investors will be looking primarily at the stability of the results, the safety profile, and whether the data will be as compelling outside the relatively specific patient population of obesity and knee arthritis
T., Hirayama, A., Soga, T
GLP-1 medications do not selectively target belly fat but produce generalized fat loss throughout the body, including significant reductions in abdominal and visceral fat